Developed by Moderna Pharmaceuticals-the same company that made headlines with its Covid-19 vaccine-the jab, known as mRNA-4359, is designed to activate the body's immune system to identify and ...

Results from the first-in-human trial of a new mRNA-based cancer vaccine are promising, as are early results from two other ...

Interim data from the Phase I dose escalation part of the mRNA cancer immunotherapy (mRNA-4359), show promise in patients with advanced solid cancers. The investigational mRNA cancer immunotherapy is ...

Interim data from the Phase I dose escalation part of the mRNA cancer immunotherapy (mRNA-4359), show promise in patients with advanced solid cancers.

Respiratory illnesses like influenza and COVID can change rapidly, requiring the nimble development and delivery of antiviral ...

Is MRNA stock a sell? These biotech stocks have what it takes to be the biggest winners through the rest of the decade and beyond. Moderna shares surged Tuesday after Canadian regulators approved ...

Mice express full-length protein ZBP1-L as well as an alternatively-spliced shorter isoform (ZBP1-S) containing only its two ...

The first patients have been dosed in a phase 3 trial of an mRNA-based seasonal influenza vaccine developed by Pfizer and BioNTech, which may offer quicker production and greater efficacy than ...

MDA5 is a critical cytoplasmic RNA sensor capable of triggering type I interferon pathways. This study shows that the E3 ...

MSD – known as Merck & Co in the US and Canada – said this morning that the phase 3 INTerpath-002 study will ... potential of V940 – also known as mRNA-4157 – which is a personalised ...